Insufficient effectiveness of 5-hydroxytryptamine-3 receptor antagonists due to oral morphine administration in patients with cisplatin-induced emesis

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1926-1930

  Shoji, Akira ^a   Toda, Mariko ^a   Suzuki, Kaneo ^a   Takahashi, Hiroshi ^a   Takahashi, Kenichi ^a   Yoshiike, Yasuhiro ^a   Ogura, Takashi ^a   Watanuki, Yuji ^a   Nishiyama, Harumi ^a   Odagiri, Shigeki ^a  

^a Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZASETRON; CISPLATIN; CORTICOSTEROID; GRANISETRON; ITASETRON; MORPHINE SULFATE; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; APPETITE; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOMITING;

EID: 0032998173     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1926     Document Type: Article

References (16)

1. American Society of Clinical Oncology: Clinical Practice Guidelines for the Treatment of Unresectable Non-Small-Cell Lung Cancer. J Clin Oncol 15:2996-3018, 1997
2. Ihde DC, Minna JD: Non-small cell lung cancer: I. Biology, diagnosis and staging. Curr Prob Cancer 15:65-104, 1991
3. Lazlo J, Lucas VS Jr: Emesis as a critical problem in chemotherapy. N Engl J Med 305:948-949, 1981
4. Lindley CM, Bernard S, Fields SM: Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatients oncology population. J Clin Oncol 7:1142-1149, 1989
5. Chevallier B: Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 26:S33-S36, 1990 (suppl 1)
6. Gebbia V, Cannata G, Testa A, et al: Ondansetron versus granisetron in prevention of chemotherapy-induced nausea and vomiting. Cancer 74:1945-1952, 1994
7. 3 receptor antagonist. Lancet 1:1461-1463, 1987
8. 3 receptor antagonist. Eur J Pharm 196:299-305, 1991
9. World Health Organization: Cancer Pain Relief, With a Guide to Opioid Availability. Geneva. Switzerland, World Health Organization, 1996
10. Pollera CF, Giannarelli D: Prognostic factors influencing cisplatin-induced emesis. Cancer 64:1117-1122, 1989
11. Bois A, Meerpohl HG: Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: A study with ondansetron. Eur J Cancer 28:450-457, 1992
12. Tonato M, The Italian Oncology Group for Clinical Research: Ondansetron plus dexamethasone: An effective combination in high-dose cisplatin therapy. J Clin Oncol 9:675-678, 1991
13. Andrews PLR, Hawthorn J: The neurophysiology of vomiting. Baillieres Clin Gastroenterol 2:141-168, 1988
14. Carpenter DO: Neural mechanisms of emesis. Can J Physiol Pharmacol 68:230-236, 1988
15. Borison HL, McCarthy LE: Neuropharmacology of chemotherapy-induced emesis. Drugs 25:8-17, 1983 (suppl 1)
16. Seynaeve C, De Mulder PHM, Verweij J: Pathophysiology of cytotoxic drug-induced emesis: Far from crystal-clear. Pharm Weekbl 13:1-6, 1991